Departament de Química Inorgànica i Orgànica, Universitat Jaume I, 12080 Castelló, Spain.
Departament de Química Física i Analítica, Universitat Jaume I, 12080 Castelló, Spain.
Molecules. 2022 Apr 14;27(8):2523. doi: 10.3390/molecules27082523.
Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported inhibitors of related proteases such as the main proteases of SARS-CoV and MERS-CoV were tested. A huge effort was then carried out by the scientific community to design, synthesize and test new small molecules acting as inactivators of SARS-CoV-2 Mpro. From the chemical structure view, these compounds can be classified into two main groups: one corresponds to modified peptides displaying an adequate sequence for high affinity and a reactive warhead; and the second is a diverse group including chemical compounds that do not have a peptide framework. Although a drug including a SARS-CoV-2 main protease inhibitor has already been commercialized, denoting the importance of this field, more compounds have been demonstrated to be promising potent inhibitors as potential antiviral drugs.
自 COVID-19 爆发以来，寻找新药的策略之一是寻找病毒 SARS-CoV-2 的主要蛋白酶（Mpro）抑制剂。最初，测试了先前报道的相关蛋白酶抑制剂，如 SARS-CoV 和 MERS-CoV 的主要蛋白酶抑制剂。然后，科学界进行了巨大的努力来设计、合成和测试新的小分子，作为 SARS-CoV-2 Mpro 的失活剂。从化学结构的角度来看，这些化合物可以分为两大类：一类是修饰肽，具有高亲和力的适当序列和反应性弹头；另一类是包括不具有肽骨架的化学化合物的多样化基团。尽管已经有一种包含 SARS-CoV-2 主要蛋白酶抑制剂的药物实现商业化，这表明该领域的重要性，但更多的化合物已被证明是有前途的强效抑制剂，可作为潜在的抗病毒药物。
